ESPE Abstracts

Blood transfusion and iron chelation are conventional treatments for β-thalassemia (BTM). However, iron overload in parenchymal organs and endocrine glands still occurs in a good number of these patients.Objective: To evaluate the prevalence of iron-related complications (short stature, growth retardation, and growth hormone deficiency) in BTM.Methods: We performed an electronic search in PubM...

Introduction: Infants whose weight is > the 90th percentile for gestational age are classified as large for gestational age (LGA). Catch-up and catch-down growth can be defined as an increase or decrease in WAZ by > 0.67 SD respectively during the infantile period. It was suggested that in LGA rapid catch-up and/or no catch-down during infancy may be associated with the development of overweight (OW) and obesity (OB) during childhood.<p class="abstex...

Introduction: Management of CAH presents unique challenges distinct from other forms of adrenal insufficiency. Higher doses of glucocorticoids are required to suppress adrenal androgen synthesis, which can lead to overtreatment. Steroid-associated adverse events (SAAE) include hypertension, hyperglycemia, and diabetes, overweight and obesity and short stature.Aim: The goal of this study was to assess the occurrence of st...

In the history of biosynthetic GH, first prediction models on long term outcome of therapy were based on large multinational cohorts of various growth disorders and have concentrated on GH dose. In this study we analyzed the 1st year and final height (FH) data in a large single center cohort (center of expertise for rare growth disorders) and compared patient outcome and predictions in GHD and SGA. Our aim was to predict treatment outcome using simple previously suggested para...

Introduction: The conventional approach to the treatment of Beta- thalassemia major (BTM) is based on the correction of hemoglobin status through regular blood transfusions and iron chelation therapy for iron overload. Allogeneic hematopoietic stem cell transplantation (HCT) remains the only currently available technique that has curative potential. No previous study compared the long-term growth and endocrinopathy changes among large cohorts of BTM patients o...

Introduction: In Qatar, the prevalence of metabolic syndrome (MetS) in children and adults is increasing in parallel with the markedly increasing trends in obesity rates. We studied the prevalence of different components of MetS, measure plasma atherogenic indexes (AIP), and linear growth in young obese nondiabetic children (< 5 years) in comparison to older obese children (6-12 years).Methods: We analyzed the anthrop...

Neonatal hypoglycemia is the most common endocrine abnormality in children, which is associated with increased morbidity and mortality. The burden and risk factors of neonatal hypoglycemia in Qatar are suggested to be high because of the high prevalence of gestational diabetes.Objective: To determine the incidence of neonatal hypoglycemia in Qatar in relation to the etiology (infants of diabetic mothers (IDM) vs infants of nondiabetic mo...

Introduction: Development of type 1 diabetes is well known in cases of type 2 autoimmune polyglandular syndrome (APS). We describe a case of APS2 who developed a hybrid form of diabetes that responded to metformin therapy.Case: The patient is a 17.5 year old male patient who has been diagnosed with APS2 at the age of 13 years with primary adrenal insufficiency and autoimmune hypothyroidism .he has been on treatment with ...

Background: Variability still exist about the growth response to growth hormone (GH) therapy in children with idiopathic short stature We describe the growth response to GH therapy ( 0.05 mg/kg/day) for > 2 years in 20 prepubertal children with idiopathic short stature (ISS) who had slow growth velocity ( < -1 SD), normal GH response to provocation and who were significantly shorter than their mid-parents height SDS MPHtSDS (-1 difference).<p class...

The availability of biosynthetic growth hormone (GH) ensures that children who are deficient can have replacement therapy, but it also has created the opportunity to treat children who are short but do not have a deficiency. Non-GH deficient short stature, without treatment, the height outcomes in most studies have failed to reach mid-parental target height. GH therapy resulted in mixed height outcomes; some reached genetic target height whereas others failed. The aim of this ...